The relevance of the adaptor protein TNF receptor-associated factor 2 (TRAF2) for signal transduction of the death receptor tumour necrosis factor receptor1 (TNFR1) is well-established. The role of TRAF2 for signalling by CD95 and the TNF-related apoptosis inducing ligand (TRAIL) DRs, however, is only poorly understood. Here, we observed that knockdown (KD) of TRAF2 sensitised keratinocytes for TRAIL-and CD95L-induced apoptosis. Interestingly, while cell death was fully blocked by the pan-caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone (zVAD-fmk) in control cells, TRAF2-depleted keratinocytes were only partly rescued from TRAIL-and CD95L-induced cell death. In line with the idea that the only partially protective effect of zVAD-fmk on TRAIL-and CD95L-treated TRAF2-depleted keratinocytes is due to the induction of necroptosis, combined treatment with zVAD-fmk and the receptor interacting protein 1 (RIP1) inhibitor necrostatin-1 fully rescued these cells. To better understand the impact of TRAF2 levels on RIP1-and RIP3-dependent necroptosis and RIP3-independent apoptosis, we performed experiments in HeLa cells that lack endogenous RIP3 and HeLa cells stably transfected with RIP3. HeLa cells, in which necroptosis has no role, were markedly sensitised to TRAIL-induced caspase-dependent apoptosis by TRAF2 KD. In RIP3-expressing HeLa transfectants, however, KD of TRAF2 also strongly sensitised for TRAIL-induced necroptosis. Noteworthy, priming of keratinocytes with soluble TWEAK, which depletes the cytosolic pool of TRAF2-containing protein complexes, resulted in strong sensitisation for TRAIL-induced necroptosis but had only a very limited effect on TRAIL-induced apoptosis. The necroptotic TRAIL response was not dependent on endogenously produced TNF and TNFR signalling, since blocking TNF by TNFR2-Fc or anti-TNFα had no effect on necroptosis induction. Taken together, we identified TRAF2 not only as a negative regulator of DR-induced apoptosis but in particular also as an antagonist of TRAIL-and CD95L-induced necroptosis.
Death receptors (DRs) constitute a subgroup of the tumour necrosis factor receptor (TNFR) superfamily and are characterised by their cytoplasmic 'death domain'. Stimulation of the prototypic DRs TNF-related apoptosis inducing ligand (TRAIL) receptor-1 (TRAILR1), TRAILR2 or CD95 by their ligands TRAIL and CD95L leads to recruitment of the adaptor proteins Fasassociated death domain (FADD) and of caspase-8. In the so formed death inducing signalling complex (DISC), caspase-8 undergoes proximity-induced maturation to the enzymatically fully active heterotetrameric caspase-8 molecule which is released from the DISC.
1,2 TNFR1 is also a DR, but acts in vivo primarily as a driver of inflammatory processes and less as an inducer of cell death. TNFR1 signals apoptosis not via a receptor-associated DISC but via a secondarily formed cytosolic caspase-8 activating complex. 3, 4 Keratinocytes express TRAILR1 and TRAILR2 as well as CD95 and can undergo apoptosis upon TRAIL or CD95L stimulation under defined circumstances. [5] [6] [7] The wellbalanced activity of DR-associated apoptotic and nonapoptotic signalling pathways in the skin is thus crucial for skin physiology. Pathological disturbance of the balance between these pathways may lead to skin cancer or inflammatory skin conditions such as psoriasis, alopecia areata or toxic epidermal necrolysis. 8, 9 Noteworthy, DRs may also trigger a caspase-independent mode of cell death. 10, 11 This caspase-independent form of DR-induced programmed cell death has been termed necroptosis and is characterised by swelling of the organelles, increased cell volume and disruption of the plasma membrane subsequently leading to inflammation. 12, 13 Mechanisms that inhibit necroptosis are critical for maintenance of tissue homeostasis. So far, induction of necroptosis has mainly been investigated after stimulation of TNFR1 or CD95, but has also been suggested for TRAIL. [14] [15] [16] At the molecular level one crucial determinant of the quality of the DR response is the serine threonine kinase RIP1. Like FADD and caspase-8, RIP1 is recruited to liganded DRs but it is also part of cytosolic caspase-8 activating complexes formed in response to TNF, genotoxic stress or depletion of the E3 ligases cellular inhibitor of apoptosis protein 1 and 2 (cIAP1 and cIAP2). 4, [17] [18] [19] [20] Dependent on the availability of the anti-apoptotic caspase-8 homologue FLICE-inhibitory protein long (FLIP-L), cIAP1/2 and the RIP1-related kinase RIP3, the cytoplasmic RIP1/caspase-8 containing complexes can lead to RIP3-dependent necroptosis 12 or caspase-8-mediated apoptosis, 4 but presumably also to RIP1-mediated activation of the anti-apoptotic classical nuclear factor κB (NFκB) pathway. 21, 22 The kinase activity of RIP1 is required for the induction of necroptosis but seems to be dispensable for its NFκB and caspase-8 stimulating activities. 23, 24 TRAF2 has been initially described as a cytosolic adaptor protein that not only interacts with the cytoplasmic part of various non-DRs of the TNFR family but also mediates recruitment of the E3 ligases cIAP1 and cIAP2. 25 It turned out that the TRAF2/cIAP complex is also indirectly recruited to some DRs, particularly to TNFR1. 26 TRAF2 and the cIAPs typically contribute to a varying extent to stimulation of signalling pathways, resulting in the activation of NFκB transcription factors and MAP kinases. While the K63 E3 ligase activity of cIAP1 and cIAP2 is of pivotal relevance there is also evidence that TRAF2 can act itself as a K48 E3 ligase of caspase-8 that triggers proteasomal degradation of the maturated enzyme. 27 However, the E3 ligase activity of TRAF2 is controversially discussed. [28] [29] [30] In the current study, we investigated the relevance of TRAF2 for the cell death response to TRAIL and CD95L stimulation. It turned out that TRAF2 is involved in protection against TRAIL-and CD95L-induced apoptosis but above all against TRAIL-and CD95L-induced necroptosis.
Results

TRAF2 knockdown sensitises
HaCaT keratinocytes for TRAIL-induced cell death. To investigate the relevance of TRAF2 for TRAIL DR-induced cell death in keratinocytes, TRAF2 was depleted in HaCaT cells by RNA interference. Cells were then stimulated with Killer-TRAIL, a highly active, commercially available form of TRAIL, and evaluated for viability and molecular markers of cell death. HaCaT keratinocytes with reduced TRAF2 levels were markedly sensitised for TRAIL-induced cell death. Crystal violet staining revealed an~16-fold lower lethal dose 50% for Killer-TRAIL-induced cell death in TRAF2 small interfering RNA (siRNA)-transfected cells as compared with cells transfected with an irrelevant control siRNA (Figure 1a ). In line with this finding, TRAIL-induced externalisation of phosphatidylserine was increased in TRAF2 knockdown (KD) cells (Figure 1b ) and came along with increased detachment from the plastic surface (Figure 1c) . TRAILinduced cell death was furthermore accompanied by activation and cleavage of caspases and this was also moderately enhanced after TRAF2 KD. Cleavage of caspase-8 and caspase-3 as well as of the caspase-3 substrate PARP and of RIP1 was equal or even more intense in the TRAF2 KD keratinocytes after 1-3 h (Figure 1d ).
TRAIL induces necroptosis in HaCaT keratinocytes upon TRAF2 KD and caspase inhibition. TRAIL-induced cell death correlated with activation of caspases. To explore whether caspase activation is required for TRAIL-induced cell death in TRAF2 KD cells or whether necroptosis contributed to overall cell death, we next analysed the effects of the pan-caspase inhibitor zVAD-fmk and of the RIP1-inhibitor necrostatin-1 (Nec) on TRAIL-induced cell death. In cells transfected with control siRNA, TRAIL-induced cell death was largely blocked by zVAD-fmk (Figures 2a and b) . Surprisingly, TRAF2 KD not only sensitised for TRAIL-induced cell death, but also changed the character of the TRAIL cell death response. In the presence of zVAD-fmk, and in marked contrast to control cells, TRAF2 siRNA-transfected cells were only partly rescued by zVAD-fmk (Figures 2a and b ). This could also be reproduced with independent functional siRNA's for TRAF2 (Supplementary Figure S8) . To confirm that caspase inhibition by zVAD-fmk was effective, we performed Western blot analysis of TRAIL-exposed TRAF2-depleted and control siRNA-transfected HaCaT cells. Treatment with zVAD-fmk indeed prevented TRAIL-induced processing of caspases-3 and -8 in control siRNA-and TRAF2 siRNA-transfected cells (Figure 2c ). Preincubation with the RIP1 inhibitor necrostatin-1 alone showed no protective effect on TRAIL-induced cell viability irrespective of TRAF2 KD (Figure 2d ). However, in contrast to zVAD-fmk, a mixture of zVAD-fmk and necrostatin-1 completely rescued TRAIL-stimulated TRAF2-depleted keratinocytes (Figure 2d ). These data indicate that TRAF2 KD sensitises keratinocytes for RIP1-mediated necroptosis under conditions of impaired caspase-8 activation.
CD95 stimulation leads to increased apoptosis and necroptosis in TRAF2 KD HaCaT keratinocytes. CD95 and the TRAIL DRs signal by quite similar mechanisms. Therefore, we next analysed CD95-mediated cell death in TRAF2 KD keratinocytes. CD95L-treated HaCaT cells with TRAF2 KD exhibited a higher sensitivity to CD95L-induced cell death as compared with controls (Figures 3a and b) . Caspase-8 and caspase-3 processing as well as cleavage of RIP1 was enhanced in TRAF2 KD HaCaT cells and was fully inhibited by preincubation with zVAD-fmk (Figure 3c ). CD95-mediated cell death, however, was fully blocked by caspase inhibition only in the control siRNA-transfected, but not in the TRAF2 siRNA-transfected HaCaT cells ( Figure 3d ). As with TRAIL, the caspase-independent form of cell death occurring in CD95-stimulated zVAD-fmk-treated TRAF2 KD cells was rescued in the presence of necrostatin-1 (Figure 3d ).
TRAF2 KD in primary keratinocytes unleashes DRinduced necroptosis when caspase activity is impaired. HaCaT cells are a spontaneously transformed keratinocyte cell line that shares many but not all properties TRAF2 inhibits necroptosis I Karl et al of primary keratinocytes. 31 We therefore analysed the effects of TRAF2 KD on TRAIL-and CD95L-induced cell death in primary keratinocytes. In contrast to HaCaT cells, primary keratinocytes express high levels of FLIP-L and are therefore largely resistant towards TRAIL-and CD95L-induced cell death. 6 Interestingly, KD of TRAF2 enabled CD95L and TRAIL to induce cell death in primary keratinocytes ( Figures  4a and d) . Western Blot analysis furthermore revealed increased caspase-3 processing in TRAF2 KD keratinocytes after CD95L stimulation, whereas caspase-8 cleavage to p43/41 remained largely unchanged (Figure 4b ). Intriguingly, preincubation with zVAD-fmk inhibited DR-induced processing of caspase-8 and caspase-3 to p18 and p20/17/15 but enhanced cell death induction in the TRAF2 KD cells (Figures  4b and c) . Co-incubation with necrostatin-1 and zVAD-fmk restored TRAIL resistance in control-transfected as well as in TRAF2 KD keratinocytes (Figure 4d ). This argues for an anti-necroptotic activity of TRAF2 in the context of DR signalling not only in HaCaT cells but also in primary keratinocytes. Figure S1 ). Altogether these data suggest (i) that RIP3 is crucial for TRAIL-induced necroptosis, (ii) that RIP3 may also enhance TRAIL-induced caspase activation and (iii) that TRAF2 antagonises both apoptosis and necroptosis induction by TRAIL.
Depletion of cytoplasmic TRAF2/cIAP complexes by Fn14 activation and a cIAP antagonist sensitise for TRAILinduced necroptosis. Artificial downregulation of TRAF2 expression by siRNA might have a physiological equivalent. We and others showed that stimulation of TRAF2-interacting receptors such as TNFR2 and fibroblast growth factorinducible 14 (Fn14) lead to recruitment of TRAF2 and TRAF2-containing complexes from the cytoplasm to a Triton X-100 insoluble compartment, [33] [34] [35] resulting in depletion of the cytoplasmic pool of TRAF2 and limitation of the availability of TRAF2 and TRAF2/cIAP complexes for other receptors. In the context of TNFR1 signalling, priming of cells with the Fn14 ligand TNF-like weak inducer of apoptosis (TWEAK) leads to a strong enhancement of TNF-induced caspase-8 activation and apoptosis. 33, 34 We thus analysed the effects of Fn14 stimulation with soluble TWEAK on TRAIL-induced cell death. In another setting we depleted intracellular cIAPs by incubating the cells with the IAP antagonist BV6. 18 As has already been observed previously, 33 priming with TWEAK exerted no or at best a minor sensitising effect on TRAIL-induced cell death in HaCaT cells in the absence of caspase-8 inhibitory means (Figure 6a ). Of note, depletion of the Triton X-100 soluble pool of TRAF2 and, accordingly, stabilisation of NFκB-inducing kinase (NIK) and processing of NFκB p100 was efficient in these cells (Figure 6e ). In the presence of zVADfmk, however, thus under necroptotic conditions, TWEAK priming resulted in a significant sensitisation for both TRAILand TNF-induced cell death (Figure 6b and Supplementary Figure S3 ). Principally similar results were obtained in cells that had been treated with the cIAP antagonist BV6 (Figures  6c and d) . The necroptotic TRAIL-TWEAK crosstalk was also evident in the RIP3 expressing HeLa transfectants, but not in the parental HeLa cells lacking RIP3 expression (Figures 6f and g and Supplementary Figure S5 ). Again treatment with the cIAP antagonist BV6 showed similar effects as TWEAK priming (Figures 6h and i) . In summary, these data show that TWEAK priming and BV6 treatment specifically sensitise for TRAIL-induced necroptosis and in this respect mimic a major effect observed with TRAF2 KD. Thus, the latter may act partly by reducing the capacity of cIAP1/2 to target RIP1.
Sensitisation towards TRAIL-induced necroptosis in TRAF2 KD cells constitutes a genuine TRAIL signalling effect and is not an indirect effect of TNF. Interference with the activity of the TRAF2/cIAP complex, for example, by use of second mitochondria-derived activator of caspases (SMAC) mimetics, as well as stimulation with soluble TWEAK can trigger in a cell-type dependent manner the induction of endogenous TNF and subsequent TNFR activation. 34, 36 To exclude that cytoplasmic downregulation of TRAF2 either by siRNA KD or by Fn14 signalling leads to sensitisation for necroptosis via upregulation of endogenous TNFα and TNFR-signalling, we performed TRAIL stimulation experiments in the presence of TNFR2-Fc (Etanercept, Enbrel), which inhibits TNFα and lymphotoxin α, or the antagonistic anti-TNFα-antibody Adalimumab (Humira) (Figure 7 ; Supplementary Figures S6 and S7 ). SK-OV3 cells, which are known to exert an apoptotic TWEAK response via an autocrine TNF loop served as a positive control to confirm that the TNF blockers used were effective (Supplementary Figure S2b) . Effects of TRAIL or CD95L stimulation under necroptotic conditions were not altered by co-incubation with TNFR2-Fc or anti-TNFα, respectively ( Figure 7 , Supplementary Figures S2a, S6 and S7) . Inhibition of classical NFκB signalling, which has a major role in TNF induction but also induces survival proteins, with the IκB kinase 2 (IKK2) inhibitor TPCA-1 did also not affect the cell death-enhancing effects of TRAF2 KD (Supplementary Figure S4) . We thus conclude that the cell death-sensitizing properties of TRAF2 KD observed in TRAIL-stimulated cells reflect a genuine effect of TRAIL-related death signalling and not an indirect TNF effect. Figure 7 TWEAK sensitises for TRAIL-induced necroptosis independent from endogenous TNF. HaCaT cells were seeded in 96-well plates and pretreated with TWEAK (200 ng/ml) or medium control overnight. Cells were then pretreated for 1 h with zVAD-fmk (40 μM), necrostatin-1 (90 μM) or a combination of both and then stimulated with TRAIL (64 ng/ml) in the presence or absence of TNFR2-Fc (Enbrel) (10 μg/ml). Viability was measured by crystal violet assay TRAF2 inhibits necroptosis I Karl et al Discussion TRAF2 is an adaptor protein that recruits cIAPs to TNFR1 and to most non-DRs of the TNF receptor family. 26 TRAF2 is important for activation of the classical NFκB pathway by these receptors but also mediates their stimulatory effects on the c-Jun N-terminal kinase pathway.
26 TRAF2 is also involved in the constitutive cytosolic degradation of NIK, a MAP3K that triggers the noncanonical NFκB signalling pathway. 37 Most TRAF2-interacting receptors can interfere with TRAF2-dependent stimulation of NIK degradation by sequestration of TRAF2 and therefore also activate the alternative NFκB pathway; 38, 39 (Figure 6e ). In the context of TNFR1 signalling, TRAF2 along with TRAF1, cIAP1 and cIAP2 furthermore antagonises caspase-8 activation and inhibits apoptosis induction. 40 Sequestration of TRAF2 and TRAF2-containing complexes by TRAF2-interacting receptors therefore also results in sensitisation for TNF-induced apoptosis. 33, 34, [41] [42] [43] [44] [45] In this study, we evaluated the relevance of TRAF2 for TRAIL-and CD95L-induced cell death. TRAF2 KD indeed lowered the LC50 of TRAIL or CD95L for more than an order of magnitude in HaCaT and HeLa cells (Figures 1a, 3a and 5a) . Noteworthy, TRAF2 KD not only reduced the LC50 of cell death induction by TRAIL and CD95L but also partly changed the quality of cell death. While control siRNA transfected HaCaT cells were fully rescued from TRAIL-and CD95L-induced cell death by the caspase inhibitor zVAD-fmk, TRAF2-depleted HaCaT were only partly protected and required a mixture of zVAD-fmk and the necroptosis inhibitor necrostatin-1 for survival (Figures 2b, d and 3d ). HeLa cells treated with control siRNA and TRAF2 siRNA were in both cases fully protected from TRAIL-induced cell death (Figure 5b ). HeLa cells, however, lack RIP3 expression and are therefore completely refractory to DR-induced necroptosis. We therefore also analysed RIP3-transfected HeLa cells with respect to the relevance of TRAF2 in TRAIL-induced cell death. In this necroptosis-competent HeLa variant, we observed roughly similar effects of TRAF2 KD on TRAILinduced cell death as in the endogenously RIP3 expressing HaCaT cells, namely enhanced TRAIL-induced necroptosis in the presence of zVAD-fmk (Figure 5b) . In sum, these data indicate that TRAF2 antagonises both DR-induced apoptosis but especially DR-stimulated necroptosis.
Initially, the survival-promoting activities of TRAF2 have mainly been investigated in the context of TNFR1 signalling and have been assigned to the ability of TRAF2 to mediate classical NFκB signalling, resulting in upregulation of NFκB-controlled anti-apoptotic and anti-necrotic proteins, including FLIP, ferritin heavy chain and manganese superoxide dismutase. [46] [47] [48] However, there is increasing evidence that TRAF2 in concert with cIAP1 and cIAP2 also antagonises TNFR1-induced cell death by an NFκB-independent mechanism. For example, TRAF2 depletion by simultaneous or delayed stimulation of TNFR2, in contrast to TNFR2 priming, does not inhibit TNFR1-induced NFκB activation but still significantly enhances TNFR1-induced apoptosis. 44 Indeed, the TRAF2-associated cIAPs have been found to inhibit TNFinduced RIP1-mediated activation of caspase-8 by K63 ubiquitination of RIP1. 49 Moreover, TRAF2 has recently been identified as a K48 ubiquitin ligase for the p18 subunit of matured heterotetrameric cytosolic caspase-8. 27 The reduction of the latter activity in TRAF2 KD cells could contribute to the sensitisation for TRAIL-and CD95L-induced caspasedependent apoptosis observed in these cells. This cIAP1/2-independent function may also explain at least in part why TWEAK, which depletes the cytosolic pool of TRAF2-cIAP1/2 complexes, and BV6, which induces degradation of cIAP1 and cIAP2, in contrast to TRAF2 KD largely fail to enhance TRAILinduced apoptosis although both treatments similar to the TRAF2 KD efficiently enhanced TRAIL-induced necroptosis ( Figure 6 ). TRAF2 has been furthermore implicated in TRAILinduced activation of the classical NFκB pathway. 22, 50, 51 In fact, reduced basal and/or TRAIL/CD95L-inducible expression of anti-apoptotic and anti-necrotic proteins in TRAF2 KD cells could explain both the enhancement of TRAIL/CD95L-induced apoptosis and of TRAIL/CD95L-induced necroptosis. TRAF2 KD, however, also sensitised cells in the presence of cycloheximide, an inhibitor of protein synthesis, and in the presence of the IKK2-inhibitor TPCA-1 (Supplementary Figure  S4) , suggesting that the pro-survival activity of TRAF2 in TRAIL-and CD95L-induced signalling is not dependent on gene induction and protein synthesis. RIP1 can promote DRinduced apoptosis but is also crucially involved in DR-induced necroptosis. As on one side, necroptotic activity of RIP1 is antagonised by cIAP1-and cIAP2-mediated ubiquitination 12 and as on the other side cIAP1 and cIAP2 are recruited to RIP1 via TRAF2, it appears plausible that the RIP1-caspase-8 complex is the main target of the pro-survival activity of TRAF2 in context of TRAIL-and CD95L-induced cell death. Thus, the sensitising effect of TRAF2 KD on TRAIL-induced necroptosis in caspase inhibited cells is possibly caused by reduced recruitment of cIAPs to RIP1.
In view of the fact that TRAF2-interacting receptors inhibit by sequestration cytosolic TRAF2-cIAP1/2 complex-related activities, such as inhibition of the alternative NFκB pathway and inhibition of TNF-induced caspase-8 activation, [40] [41] [42] [43] [44] [45] we evaluated the effect of Fn14 stimulation on TRAIL-induced cell death. Fn14 is a broadly expressed TRAF2-interacting receptor of the TNF receptor family that, after stimulation by its ligand TWEAK, strongly triggers the alternative NFκB pathway. 52, 53 Moreover, priming cells for a few hours with TWEAK results in depletion of the Triton X-100 soluble cytosolic pool of TRAF2-cIAP1/2 complexes and reduced TNF-induced TNFR1-associated ubiquitination of RIP1, which, as mentioned before, is mediated by the cIAPs. 33 TWEAK priming thus leads to attenuated activation of the classical NFκB pathway and under appropriate conditions to a tremendous sensitisation for TNF-induced cell death (200-1000-fold). 33 In the previous cited study no major effect of TWEAK priming on TRAIL-induced apoptosis has been found. 33 However, the effect of TWEAK on TRAIL-induced cell death had been investigated in the absence of caspase-8 inhibition and thus under conditions where DR-induced necroptosis was blocked by caspase-8.
12 As in our current study the cell death sensitising effect of the TRAF2 KD was most prominent in the context of TRAIL-and CD95L-induced necroptosis, we looked for a possible TRAIL-TWEAK crosstalk under necroptotic conditions (caspase-8 inhibition and RIP3 expression). Indeed, under such conditions, we observed a significant enhancement of TRAIL-induced cell TRAF2 inhibits necroptosis I Karl et al death by TWEAK and by preincubation with the SMAC mimetic BV6 (Figure 6 ). The fact that TWEAK sensitises cells for apoptosis and necroptosis in the context of TNF signalling but only for necroptosis in the context of TRAIL signalling might reflect the differential relevance of the cytosolic RIP1-caspase-8 complex for TNF-and TRAIL-induced apoptosis. In TRAIL-induced apoptosis caspase-8 is primarily activated in the receptor-associated signalling complex in a RIP1-independent manner. In the context of TNFR1-induced apoptosis, however, caspase-8 activation mainly takes place in the secondarily formed cytosolic RIP1-caspase-8 complex. This may also explain why BV6 primarily enhances TRAILinduced necroptosis. An ability of TRAIL to induce necroptosis has often been suggested so far but only a very limited number of studies have really shown necroptosis induction by TRAIL. 14, 16 Our data confirm these observations and additionally prove in the experiments with TNFR2-Fc and with anti-TNFα-antibody ( Figure 7,Supplementary Figures S2) that the TRAIL effect is not mediated via an autocrine TNF loop but is a direct effect of TRAIL. Most importantly, however, by showing that TRAF2 KD, TWEAK priming and BV6 treatment result in enhanced TRAIL-induced necroptosis in the presence of a caspase inhibitor, we give several lines of independent evidence for an inhibitory role of TRAF2/cIAP complexes in TRAIL-and CD95L-induced necroptotic signalling.
Materials and Methods
Materials. Antibodies with the following specificities were used for Western blot analysis: TRAF2, β-actin (abcam, Cambridge, UK), Caspase-3, cIAP1, cIAP2 (Cell signaling, Danvers, MA, USA), Caspase-8 (Enzo Life Sciences, Lausen, Switzerland), PARP, Cul3 (BD Pharmingen, Heidelberg, Germany), α-Tubulin (Millipore, Billerica, MA, USA) and RIP3 (Imgenex, San Diego, CA, USA). HRP-conjugated goat anti-mouse IgG1, goat anti-mouse IgG2a, goat anti-mouse IgG2b and donkey anti-rabbit antibodies were obtained from Southern Biotech (Birmingham, AL, USA) and Dianova (Hamburg, Germany). Killer-TRAIL was purchased from Alexis biosciences (Carlsbad, CA, USA). The pan-caspase-inhibitor zVAD-fmk was obtained from Bachem (Heidelberg, Germany). Necrostatin-1 was purchased from Enzo Life Sciences (Lausen, Switzerland). Fc-CD95L and Flag-TWEAK were produced as previously described. 33 TRAF2 siRNA (HS-TRAF2_4, sequence as follows: 5′-GGACCAAGACAAGAUUGAATT-3′), alternate TRAF2 siRNA's (HS-TRAF2_5, sequence: 5′-CGAGGGCAUAUAUGAAGAATT-3′; HS TRAF2_6, sequence: 5′-GUUCGGCCUUCCCAGAUAATT-3′; HS TRAF2_7, sequence: 5′-GC UGCGGAGCAGACGUGAATT-3′) and negative control siRNA were provided by Qiagen (Hilden, Germany). siRNA transfection was performed with Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA).
Cell culture. The spontaneously transformed keratinocyte line HaCaT was provided by P. Boukamp and cultured as previously described 31 in Dulbecco's modified Eagle's medium supplemented with 10% foetal calf serum at 37°C with 5% CO 2 . Primary keratinocytes were separated from neonatal foreskin as previously described, 6 cultured in KGM (Promocell, Heidelberg, Germany) and used between passages 2-5. HeLa cells transfected with empty vector and HeLa stably transfected with RIP3 were cultured in Dulbecco's modified Eagle's medium supplemented with 10% foetal calf serum at 37°C with 5% CO 2 . SK-OV3 cells were cultured in RPMI supplemented with 10% foetal calf serum at 37°C with 5% CO 2 .
siRNA transfection. For transient transfection, cells were incubated with Lipofectamine 2000 and siRNA according to the Lipofectamine transfection protocol. Briefly, 1 × 10 × 6 cells were seeded in a 10 cm culture dish. On the following day, Lipofectamine (30 μl) and siRNA (20 μM) were equilibrated in Opti-MEM (3 ml) and slowly added to the cells. Experiments were performed at day 1-5 post transfection. KD efficiency was confirmed by Western blot analysis and typically found between 60 and 90%. All of the experiments were performed with TRAF2_4 siRNA from Qiagen, but we could reproduce our results with other functional siRNAs for TRAF2 (Supplementary Figure S8) .
Flow cytometry. Externalisation of phosphatidylserine to the outer membrane was measured with the PE Annexin V Apoptosis Detection Kit (BD BioSciences Pharmingen, Heidelberg, Germany) according to the manufacturer's protocol. Briefly, cells were seeded into six-well plates at a density of 1 × 10 × 5/well 1 day prior to experiments. On the day of the experiment, the medium was changed and cells were stimulated with Killer-TRAIL or Fc-CD95L for the indicated times (see results). Cells were then detached, washed with ice-cold PBS and resuspended in 100 μl 1 × binding buffer. As a positive control for necrosis, cells were exposed to heat-shock (55°C for 30 min). 54 Next, 5 μl Annexin V and 5 μl 7-AAD were added to each sample and cells were incubated for 15 min in the dark. Cells were measured on a FACSCanto flow cytometer (BD BioSciences, Heidelberg, Germany) and data was analysed using the FACS DIVA software (BD BioSciences).
Western blot analysis. To prepare total cell lysates, cells were harvested, washed with PBS and directly lysed in SDS sample buffer (2% SDS, 10% glycerol, 10% β-mercaptoethanol, 6% 1 M TRIS pH 6.8, dH 2 O, bromophenol blue). To analyse the Triton X-100 soluble protein fraction, cells were lysed in Triton X-100 lysis buffer (1% Triton X-100, 10% glycerol, 3% 1 M TRIS pH 7.4, 6% 2 M NaCl, dH 2 O) for 30 min on ice. Thereafter, the lysates were cleared by centrifugation for 15 min at 13 000 × g, mixed with SDS sample buffer and boiled at 95°C for 5 min. Lysates were separated by SDS-polyacrylamide gel electrophoresis in NuPage 4-12% Bis-Tris gels from Life technologies and transferred to nitrocellulose membranes (Amersham, GE Healthcare, Freiburg, Germany). After blocking nonspecific binding sites by incubation in Tris-or phosphate-buffered saline containing 0.1% Tween 20 and 8% dry milk, Western blot analyses were carried out with primary antibodies of the specificity of interest and horseradish peroxidaseconjugated secondary antibodies (Southern Biotech) using ECL Western blotting detection reagents (Pierce Thermo Scientific, Schwerte, Germany). 
